Mike Nally is the Chief Executive Officer of Generate Biomedicines and is a CEO-Partner at Flagship Pioneering. He has significant experience leading global organizations and is passionate about working with teams and partners to bring innovations to patients. Since joining Generate Biomedicines in 2021, Mike led the company’s $370 million Series B financing to advance its pioneering generative biology platform and secured its first research collaboration with Amgen, which includes discovering and creating protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. Amgen is paying $50 million in upfront funding for the initial five programs with a potential transaction value of $1.9 billion, plus future royalties, and will have the option to nominate up to five additional programs at additional cost. Before Generate, Mike spent several years at Merck & Co. Most recently, he served as Chief Marketing Officer, responsible for Global Marketing and Brand Strategy across a vast portfolio of innovative medicines and vaccines, exceeding $40 billion in revenue. Previously, Mike served as President of Global Vaccines and ran the company's businesses in Sweden and the UK. Mike currently serves on the Board of Directors of Flagship’s Harbinger Health and PPG Industries, where he is a member of the PPG Audit and Technology and Environment Committees. Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.
